Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
Pfizer(PFE) stock is priced at $25.45, giving the company a market capitalization of 144.67B. It carries a P/E multiple of 15.00 and pays a dividend yield of 6.7%.
As of 2025-12-01, Pfizer(PFE) stock has fluctuated between $25.38 and $25.94. The current price stands at $25.45, placing the stock +0.3% above today's low and -1.9% off the high.
Pfizer(PFE) shares are trading with a volume of 19.04M, against a daily average of 59.64M.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.69 and a 52-week low of $20.92.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.69 and a 52-week low of $20.92.
PFE News
One drug developer could be on the cusp of AI-powered glory. Shares of the pharmaceutical giant Pfizer (PFE 0.04%) have suffered over the last three years, fal...
Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong leadership positions in distinct the...
Wondering if Pfizer’s current share price truly reflects its value? You’re not alone, and now might be the perfect time to dig into what the numbers are telling...
Analyst ratings
56%
of 27 ratingsMore PFE News
Key Points Pfizer and Johnson & Johnson are healthcare leaders and faithful dividend payers. Home Depot is facing a difficult operating environment, but its c...
Valneva SE (NASDAQ:VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA1...
The weight loss drug market may approach almost $100 billion by the end of the decade. The words "Ozempic" and "Wegovy" almost have become household names as t...
Pfizer is trying to prove it can grow again. After a year of cost-cutting and strategic deals, the drugmaker’s $10 billion purchase of Metsera is just one part...
Monday’s total option volume of 62.3 million contracts resulted in net open interest growth of 9.92 million calls and 6.07 million puts. NVIDIA (NVDA), Tesla (T...
This big pharma stock should be even more appealing to investors amid market turbulence. You may have noticed that the markets are exceptionally volatile at th...
Pfizer and Astellas Pharma recently announced that the FDA approved PADCEV, combined with Keytruda, as a perioperative treatment for adults with muscle-invasive...